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Haydar Frangoul,1 Li Wang,2 Frank E. Harrell, Jr.,2 Richard Ho,1 Jennifer Domm1Preengraftment syndrome (PES) is a knowncomplication following unrelated cord blood transplant (CBT) that
has not beenwell characterized.We sought to determine the incidence and clinical outcomeof PES among 326
patients\18 years of age who were prospectively enrolled on a multicenter CBT trial. All patients received
a myeloablative (MA) transplant and a single cord blood unit (CBU). PES developed in 20% of the patients at
a median of 10 days (range: 5-24). Patients receiving a CBU with a total nucleated cell (TNC) count of.5
107/kg had significantly higher risk of developing PES (P5.02). Therewere significantly higher rates of grade II-
V (P\.001), grade III-IV (P\.001) acute and chronic (P5.002) graft-versus-host disease (aGVHD, cGVHD) in
those who developed PES. In a multivariate analysis, PES did not significantly affect overall survival (OS) (P5
.38). We conclude that PES is common following CB transplant (CBT) and additional more intensive immune
suppression might be considered to decrease the risk of developing aGVHD and cGVHD.
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Preengraftment syndrome (PES) is a poorly
defined clinical entity following hematopoietic stem
cell transplant (HSCT). Early immune reactions, cyto-
kine storm, or PES have been described following
unrelated cord blood transplant (CBT) in adult pa-
tients with an incidence of 23% to 78% [1-4]. The
classic clinical manifestations of this syndrome are
high fever in the absence of infection and diffuse ery-
thematous skin rash resembling acute graft-versus-
host disease (aGVHD) with or without fluid retention.
Patients generally develop this syndrome as early as 5
days posttransplant, and often respond to a short
course of corticosteroid therapy. This syndrome is dis-
tinct from aGVHD in its timing as well as its manifes-
tations. Prior studies failed to show any correlation
between PES and subsequent risk of GVHD. Limita-
tions of prior studies include retrospective analysis,
small numbers of patients, and inclusion of patients
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comprehensive analysis of the incidence, risk factors
for developing PES, and clinical outcome of 326 pedi-
atric patients following CBT enrolled on amulticenter
clinical trial.PATIENTS AND METHODS
The cord blood transplant (COBLT) study is
a multi institutional trial of CBT sponsored by theNa-
tional Heart, Lung and Blood Institute (NHLBI)
branch of the National Institutes of Health. A total
of 364 adult and children were prospectively enrolled
on the study between 1999 to 2003. The protocol
was approved by the institutional review board (IRB)
of all participating centers. Data from the study were
made available by the NHLBI for analysis via a limited
data agreement with Vanderbilt University. The anal-
ysis was approved by the IRB of Vanderbilt University
Medical Center. Three hundred twenty-six patients
#18 years of age who lacked HLA matched related
donors with malignant and nonmalignant disease
were enrolled. Only subjects receiving 1 cord blood
unit (CBU) were eligible. Searches for CBU were
conducted by using low/intermediate-resolution
molecular typing for HLA class I (A and B) and
high-resolution molecular typing for HLA DRB1.
Selection of the unit was based on providing the high-
est number of total nucleated cell (TNC) count and
matching at a minimum of 4/6 HLA loci.1485
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The conditioning regimen consisted of busulfan
(Bu), cyclophosphamide (Cy), and antithymocyte
globulin (ATG) (equine) for patients with nonmalig-
nant diseases. For patients with malignant diseases
the conditioning regimen consisted of total body irra-
diation (TBI), Cy, and ATG. One stratum evaluated
the safety of Bu, melphalan (Mel), and ATG in young
patients and those who were not able to tolerate TBI.
The details of the preparative regimens has been pre-
viously reported [5-7]. GVHD prophylaxis consisted
of methylprednisolone 0.5 mg/kg twice daily on day
11 through 14 and then 1 mg/kg twice daily from
day 15 to day 119 or until the first day the absolute
neutrophil count (ANC) reached 500/mL, at which
time the dose was tapered at the rate of 0.2 mg/kg/
week. Cyclosporine was started on day23 and contin-
ued until at least day 180. Then the dose was tapered at
the rate of 5% of the initial dose per week if the recip-
ients had no evidence of GVHD.Table 1. Patient and Transplant Characteristics
Number of patients 326
Median age in years (range) 4.65 (range: 0.04-17.9)
Sex, male/female 197/129
Recipient ethnicity
Caucasian 240
African American 45
Other 41
Performance status
>80 263
#80 63
Median TNC (107/kg) (range) 6.94 (0.08-80.9)
Diagnosis
Malignant disease 229
Lymphoid 128
Myeloid 65
Other 36
Nonmalignant disease 97
Immune deficiency 24Definitions
Neutrophil engraftment was defined as achieving
an ANC of at least 500/mL for 3 consecutive measure-
ments on different days and demonstrated donor
chimerismof.90%.The grading of aGVHDfollowed
the GVHD consensus grading scheme [8]. An algo-
rithm calculated the maximum GVHD clinical grade
based on the weekly organ staging in skin, upper and
lower gastrointestinal tract, and liver. This calculated
organ stage was decreased by 1 stage if a listed specific
differential diagnosis was reported for either gastroin-
testinal tract or liver. An independent panel reviewed
all weekly records and assigned eachpatient a finalmax-
imumgrade, similar to themethods described byWeis-
dorf et al. [8]. PES, or ‘‘cytokine storm,’’ as it was
referred to in the protocol and data forms, was defined
as unexplained fever in the absence of documented in-
fection and diffuse erythematous skin rash prior to neu-
trophil engraftment. The protocol recommended
therapy for treatment of PES was methylprednisolone
at a dose of 500 mg/m2 given in 2 divided doses.Storage diseases 69
Other 4
Conditioning regimen
TBI/Cy/ATG 195
Bu/Cy/ATG 97
Bu/Mel/ATG 34
HLA match
6 of 6 or 5 of 6 148
4 of 6 or 3 of 6 178
Recipient CMV
Positive 139
Negative 180
Inconclusive or not tested 7
TNC indicates total nucleated cell count; TBI, total body irradiation; Cy,
cyclophosphamide; ATG, antithymocyte globulin; Bu, busulfan; Mel, mel-
phalan; CMV, cytomegalovirus.Statistical Analyses
Time to chronic GVHD (cGVHD) and preen-
graftment syndrome were analyzed using proportional
subdistribution hazards regression model considering
death as the competing event. Time to neutrophil
engraftment and aGVHD were analyzed using
extended proportional hazards regression model treat-
ing death as the competing event and preengraftment
syndrome as the time-dependent covariate. All statisti-
cal analyses were done with R software (version 2.8.1).RESULTS
There were 326 patients with a median age of 4.65
years (range: 0.04-17.9) who were included in this anal-
ysis. The majority of patients (70%) had malignant
diseases and the majority of those received a TBI-based
preparative regimen. The median TNC count was 6.94
 107/kg (range: 0.08-80.9) and 45% of the patients
received a HLA matched or single antigen mismatch
cord blood. The median follow-up of surviving patients
is 21 months (range: 3-64). Patient’s characteristics are
listed in Table 1. Sixty-four patients (20%) developed
PES at a median of 10 days (range: 5-24). Patients who
developedPESwere younger (median age of 2.47 versus
5.57 years) and were more likely to have nonmalignant
disease (48% versus 25%). The median precryopre-
served TNC infused was 8.58  107/kg (range: 1.54-
27.49) in those who developed PES compared to 6.68
 107/kg (range: 0.08-80.90) for those who did not.
After adjusting for patients age, sex, performance status,
HLA match (6/6 or 5/6 versus 4/6 or 3/6 match), and
cytomegalovirus (CMV) status, patients with nonmalig-
nant disease and those who received a nucleated cell
(NC) count of .5  107/kg had significantly higher
risk of PES, P5 .05 and5 .02, respectively. The cumu-
lative incidence of neutrophil engraftment at day 100 in
those with PES was 0.84 (95% confidence interval [CI]
0.80-0.89) compared to 0.77 (95% CI 0.75-0.80) in
Figure 1. Cumulative incidenceof cGVHDat 1 year for patientswith PES
is 37% (95% CI, 23-51) compared to those without 16% (95% CI 10-21).
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engraftment was 25.5 days (15-45 days) for patients
with PES and 23 days (11-90 days) for those without
PES. The median time to developing grade II-IV
aGVHD among those with and without PES was 15
and 23 days, respectively. After controlling for patient’s
age, gender, disease (malignant versus nonmalignant),
HLA match (6/6 and 5/ 6 versus other), performance
status, CMV status, and total cell count, there was sig-
nificantly increased risk of grade II-IV (P\0.01) and
more severe grade III-IV (P\0.001) aGVHD among
those with PES. Among patients who survived .100
days, the probability of developing cGVHD is signifi-
cantly higher in patients with history of PES (P 5
.002) (Figure 1). In a multivariate analysis, patients
with history of PES had a significantly higher risk of de-
veloping cGVHD (P 5 .0012) after adjusting for pa-
tient’s age, sex, disease (malignant versus
nonmalignant), HLAmatch (6/6 and 5/ 6 versus other),
performance status, CMV status, and total cell count.
Using Cox regression analysis, overall survival (OS)
was significantly worse among patients with malignant
disease (hazard ratio [HR] 1.73, 95% CI 1.07-2.80,
P 5 .025), female patients (HR 1.78, 95% CI 1.27-
2.49 , P\ .001), and those who were CMV positive
(HR 1.46, 95% CI 1.04-2.06, P 5 .029). In this multi-
variable model, PES did not significantly affect OS
(HR 0.81, 95% CI 0.50-1.30, P5 .38).DISCUSSION
The etiology of PES is not well known. Some
reports suggested that this clinical entity is mediated
by a cytokine storm that is thought to contribute to
this clinical syndrome [1,9]. PES seems to be a distinctclinical syndrome from engraftment syndrome, which
has been described immediately prior to engraftment
in autologous and allogeneic HSCT patients [10,11].
Prior studies have failed to identify a specific risk factor
for developing PES, although 1 study suggested that
using methotrexate containing GVHD prophylaxis
might reduce its incidence [3]. Patel et al. [4] recently
reported on their centers experience with 52 patients
who received unrelated cord blood after MA (n 5 36)
and NMA (n 5 16) conditioning regimens. The inci-
dence of PES in that study was 31%, and the authors
did not find an association between PES, teatment-
related mortality (TRM), and aGVHD or cGVHD.
Although all patients in that study received identical
GVHD prophylaxis, the numbers were too small to be
able to detect any differences. In our analysis, patients
receiving a TNC of .5  107/kg have a significantly
higher risk of developing PES. The trend toward in-
creased risk in patientswithnonmalignant diseasemight
be because of using chemotherapy-based preparative
regimen compared to TBI-based regimen in the major-
ity of patients with malignant diseases. Additional stud-
ies should be performed to better understand the effect
of the preparative regimen on developing PES. Our
study found a strong association between PES and the
development of severe aGVHD and cGVHD. This is
a novel finding that has not been reported in prior retro-
spective analysis that included patients receiving various
GVHD prophylaxis, supportive care regimens, and
smaller number of patients. The strong association be-
tween PES and GVHD raises the question if the preen-
graftment syndrome represents an early formofGVHD
or hyperacute GVHD that has been described in
patients following related and unrelated donor trans-
plant [12,13]. Hyper-aGVHD has been associated
with increased risk of transplant-related mortality in
recipients of unrelated donor stem cell transplant [12].
In our study we do not have a biopsy to confirm that
the rash observed in patients with PES was not early or
hyper-aGVHD. One limitation of our study is the lack
of response data to increased dose of steroids, but in
amultivariable analysis PES did not adversely affectOS.
We conclude that PES is a common complication
following unrelated CBT and is associated with signif-
icantly higher risk of aGVHD and cGVHD. Future
studies should be aimed at better understanding the
etiology of PES and weather using additional immune
suppression in patients who develop PES could
decrease the risk of developing aGVHD and cGVHD.ACKNOWLEDGMENTS
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